MaxCyte Stock Price, News & Analysis (NASDAQ:MXCT) $4.80 +0.05 (+1.05%) (As of 10:33 AM ET) Add Compare Share Share Today's Range$4.64▼$4.8050-Day Range$2.60▼$4.8752-Week Range$2.45▼$6.11Volume108,986 shsAverage Volume591,131 shsMarket Capitalization$497.18 millionP/E RatioN/ADividend YieldN/APrice Target$9.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media MaxCyte MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside100.0% Upside$9.50 Price TargetShort InterestHealthy3.25% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.62Based on 4 Articles This WeekInsider TradingSelling Shares$60,050 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.43) to ($0.46) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.35 out of 5 starsMedical Sector273rd out of 948 stocksCommercial Physical Research Industry7th out of 13 stocks 3.5 Analyst's Opinion Consensus RatingMaxCyte has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.50, MaxCyte has a forecasted upside of 100.0% from its current price of $4.75.Amount of Analyst CoverageMaxCyte has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.25% of the float of MaxCyte has been sold short.Short Interest Ratio / Days to CoverMaxCyte has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MaxCyte has recently decreased by 8.90%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMaxCyte does not currently pay a dividend.Dividend GrowthMaxCyte does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MXCT. Previous Next 3.1 News and Social Media Coverage News SentimentMaxCyte has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for MaxCyte this week, compared to 1 article on an average week.Search Interest2 people have searched for MXCT on MarketBeat in the last 30 days. MarketBeat Follows1 people have added MaxCyte to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MaxCyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $60,050.00 in company stock.Percentage Held by InsidersOnly 6.00% of the stock of MaxCyte is held by insiders.Percentage Held by Institutions62.25% of the stock of MaxCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for MaxCyte are expected to decrease in the coming year, from ($0.43) to ($0.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MaxCyte is -12.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MaxCyte is -12.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMaxCyte has a P/B Ratio of 2.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About MaxCyte Stock (NASDAQ:MXCT)MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.Read More MXCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MXCT Stock News HeadlinesDecember 1, 2023 | americanbankingnews.comCraig Hallum Initiates Coverage on MaxCyte (NASDAQ:MXCT)November 9, 2023 | finanznachrichten.deMaxCyte, Inc.: MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue GuidanceDecember 1, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 8, 2023 | morningstar.comMaxCyte Inc MXCTOctober 5, 2023 | bizjournals.comMaxCyte shares plunge after Rockville biotech firm sharply lowers 2023 revenue outookOctober 5, 2023 | markets.businessinsider.comCell Engineering MaxCyte Faces Challenge, Analysts Express Concerns Over Near-Term Prospects Amid Revenue DeclineOctober 5, 2023 | finanznachrichten.deMaxCyte, Inc: MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue GuidanceOctober 5, 2023 | benzinga.comMaxCyte, Rivian Automotive And Other Big Stocks Moving Lower In Thursday's Pre-Market SessionDecember 1, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.October 5, 2023 | finance.yahoo.comThe past year for MaxCyte (LON:MXCT) investors has not been profitableOctober 5, 2023 | investorplace.comWhy Is MaxCyte (MXCT) Stock Down 21% Today?October 4, 2023 | marketwatch.comMaxCyte Shares Sink 21% Amid Lower-Than-Expected FY Revenue ViewsSeptember 6, 2023 | finanznachrichten.deMaxCyte, Inc: MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of BioprocessingSeptember 6, 2023 | finance.yahoo.comMaxCyte Appoints Ali Soleymannezhad as Executive Vice President of BioprocessingSeptember 5, 2023 | finance.yahoo.comMaxCyte to Participate in Baird Global Healthcare ConferenceAugust 11, 2023 | finanznachrichten.deMaxCyte, Inc.: MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 GuidanceJuly 10, 2023 | finanznachrichten.deMaxCyte, Inc: MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular TherapiesJuly 8, 2023 | finance.yahoo.comMaxCyte, Inc. (LON:MXCT) is largely controlled by institutional shareholders who own 77% of the companyJune 9, 2023 | seekingalpha.comPRTS, CRBU and NDLS are among after hour moversMay 30, 2023 | msn.comMaxCyte: Engineering The Next Biotech WaveMay 18, 2023 | finanznachrichten.deMaxCyte, Inc: MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 GuidanceMay 12, 2023 | msn.comRecap: MaxCyte Q1 EarningsMay 11, 2023 | seekingalpha.comMaxCyte, Inc. 2023 Q1 - Results - Earnings Call PresentationMay 10, 2023 | finance.yahoo.comMaxCyte, Inc. (MXCT) Reports Q1 Loss, Lags Revenue EstimatesMay 10, 2023 | finance.yahoo.comMaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 GuidanceMay 4, 2023 | finance.yahoo.comMaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell PlatformApril 12, 2023 | finance.yahoo.comMaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023See More Headlines Receive MXCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2023Today12/01/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/20/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MXCT CUSIPN/A CIK1287098 Webmaxcyte.com Phone301-944-1700Fax301-944-1703Employees125Year FoundedN/APrice Target and Rating Average Stock Price Target$9.50 High Stock Price Target$12.00 Low Stock Price Target$7.00 Potential Upside/Downside+100.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,570,000.00 Net Margins-98.44% Pretax Margin-98.44% Return on Equity-15.35% Return on Assets-13.55% Debt Debt-to-Equity RatioN/A Current Ratio12.87 Quick Ratio12.12 Sales & Book Value Annual Sales$38.05 million Price / Sales12.93 Cash FlowN/A Price / Cash FlowN/A Book Value$2.25 per share Price / Book2.11Miscellaneous Outstanding Shares103,576,000Free Float97,361,000Market Cap$491.99 million OptionableOptionable Beta0.84 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Douglas Arthur Doerfler (Age 67)Founder, President, CEO & Executive Director Comp: $1.2MDr. Cenk Sumen Ph.D. (Age 49)Chief Scientific Officer Comp: $575.6kMr. Maher Masoud (Age 48)Executive VP, General Counsel & Secretary Comp: $612.07kMr. Douglas J. Swirsky CFA (Age 54)CPA, Chief Financial Officer Mr. Ronald Evan Holtz CPA (Age 65)Ph.D., Executive Vice President of Administration Comp: $649.38kMr. Sean MenarguezDirector of Investor RelationsMr. Thomas Michael Ross (Age 62)Executive Vice President of Global Sales & Marketing Mr. Jack HorganVice President of Corporate DevelopmentDr. J. Stark Thompson Ph.D. (Age 81)Consultant Comp: $84.71kDr. James Brady Ph.D.Senior VP of Technical Applications & Customer SupportMore ExecutivesKey CompetitorsOmniAbNASDAQ:OABIAbsciNASDAQ:ABSITyra BiosciencesNASDAQ:TYRAPulse BiosciencesNASDAQ:PLSERAPT TherapeuticsNASDAQ:RAPTView All CompetitorsInsiders & InstitutionsAmerican Century Companies Inc.Sold 2,733 shares on 11/30/2023Ownership: 1.647%John Joseph JohnstonSold 5,000 sharesTotal: $22,950.00 ($4.59/share)Deutsche Bank AGBought 6,915 shares on 11/24/2023Ownership: 0.036%Ameriprise Financial Inc.Sold 10,461 shares on 11/15/2023Ownership: 1.264%Legal & General Group PlcBought 14,288 shares on 11/15/2023Ownership: 0.072%View All Insider TransactionsView All Institutional Transactions MXCT Stock Analysis - Frequently Asked Questions Should I buy or sell MaxCyte stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MaxCyte in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MXCT shares. View MXCT analyst ratings or view top-rated stocks. What is MaxCyte's stock price target for 2024? 3 brokerages have issued 12 month price objectives for MaxCyte's shares. Their MXCT share price targets range from $7.00 to $12.00. On average, they anticipate the company's share price to reach $9.50 in the next twelve months. This suggests a possible upside of 100.0% from the stock's current price. View analysts price targets for MXCT or view top-rated stocks among Wall Street analysts. How have MXCT shares performed in 2023? MaxCyte's stock was trading at $5.46 at the beginning of 2023. Since then, MXCT shares have decreased by 13.0% and is now trading at $4.75. View the best growth stocks for 2023 here. When is MaxCyte's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024. View our MXCT earnings forecast. How were MaxCyte's earnings last quarter? MaxCyte, Inc. (NASDAQ:MXCT) issued its quarterly earnings results on Wednesday, November, 8th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.01. The company had revenue of $8.01 million for the quarter, compared to the consensus estimate of $7.90 million. MaxCyte had a negative net margin of 98.44% and a negative trailing twelve-month return on equity of 15.35%. What guidance has MaxCyte issued on next quarter's earnings? MaxCyte issued an update on its third quarter 2023 earnings guidance on Wednesday, October, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $7.80 million-$8.00 million, compared to the consensus revenue estimate of $11.35 million. When did MaxCyte IPO? (MXCT) raised $150 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 12,000,000 shares at $11.50-$13.50 per share. Who are MaxCyte's major shareholders? MaxCyte's stock is owned by a number of institutional and retail investors. Top institutional investors include Stonepine Capital Management LLC (3.63%), Massachusetts Financial Services Co. MA (1.89%), American Century Companies Inc. (1.65%), River & Mercantile Asset Management LLP (1.42%), Ameriprise Financial Inc. (1.26%) and Northern Trust Corp (0.77%). Insiders that own company stock include Casdin Partners Master Fund, L, Douglas Doerfler, John Joseph Johnston, Richard Douglas and Thomas M Ross. View institutional ownership trends. How do I buy shares of MaxCyte? Shares of MXCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:MXCT) was last updated on 12/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MaxCyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.